Danusertib (PHA-739358) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and ABL/T315I62; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or dasatinib. Here, ABL1 is linked to breast cancer.